Latest News

Medicaid coverage of HPV vaccine in adults: Implications in dermatology


 

FROM JAMA DERMATOLOGY

“Vaccines can be cost-prohibitive for patients without insurance coverage, so we hope that dermatologists will be more likely to recommend the HPV vaccine to patients 27-45 years of age if they know that it is likely covered by insurance,” Dr. Noe noted.

Dr. Megan H. Noe, Department of Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Boston

Dr. Megan H. Noe

However, “time may be a barrier for many dermatologists who have many important things to discuss with patients during their appointments,” she said. “We are currently working on developing educational information to help facilitate this conversation,” she added.

Looking ahead, she said that “additional research is necessary to create vaccine guidelines specific to dermatology patients and dermatology medications, so we can provide clear recommendations to our patients and ensure appropriate insurance coverage for all necessary vaccines.”

Vaccine discussions

“I think it’s great that many Medicaid plans are covering HPV vaccination,” said Karl Saardi, MD, of the department of dermatology, George Washington University, Washington, who was asked to comment on the study. “I routinely recommend [vaccination] for patients who have viral warts, since it does lead to improvement in some cases,” Dr. Saardi, who was not involved in the current study, said in an interview. “Although we don’t have the HPV vaccines in our clinic for administration, my experience has been that patients are very open to discussing it with their primary care doctors.”

Although the upper age range continues to rise, “I think getting younger people vaccinated will also prove to be important,” said Dr. Saardi, director of the inpatient dermatology service at the George Washington University Hospital.

The point made in the current study about the importance of HPV vaccination in patients with hidradenitis suppurativa is also crucial, he added. “Since chronic skin inflammation in hidradenitis drives squamous cell carcinoma, reducing the impact of HPV on such cancers makes perfect sense.”

The study received no outside funding. Dr. Noe disclosed grants from Boehringer Ingelheim unrelated to the current study. Dr. Saardi had no financial conflicts to disclose.

Pages

Recommended Reading

‘Unappreciated’ ties between COVID and gut dysbiosis
Clinician Reviews
Mid-October flulike illness cases higher than past 5 years
Clinician Reviews
Shortage reported of antibiotic commonly used for children
Clinician Reviews
FDA expands tenofovir alafenamide (Vemlidy) use to adolescents with chronic HBV
Clinician Reviews
COVID bivalent booster better vs. recent Omicron subvariants: Pfizer
Clinician Reviews
Man with COVID finally tests negative after 411 days
Clinician Reviews
CDC warns of early uptick in respiratory disease
Clinician Reviews
Promising new antibiotic emerges for treating UTIs
Clinician Reviews
World falls short on HBV, HCV elimination targets
Clinician Reviews
Children and COVID: New cases increase for second straight week
Clinician Reviews